Phenylpropanolamine increases plasma caffeine levels
- PMID: 2357862
- DOI: 10.1038/clpt.1990.93
Phenylpropanolamine increases plasma caffeine levels
Abstract
The effects of the widely consumed drugs caffeine and phenylpropanolamine are mediated through activation of the central and sympathetic nervous systems. Severe, life-threatening, and occasionally fatal hypertensive reactions have been reported after their combined use. This study examined the possible pharmacokinetic interaction of phenylpropanolamine and caffeine. Sixteen normal subjects received combinations of caffeine, phenylpropanolamine, and placebo. In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01). Physical side effects were more frequent after the phenylpropanolamine-caffeine combination than after either drug alone or after placebo. Greater increases in both systolic and diastolic blood pressures occurred after the combination than after either drug alone. Because caffeine levels can be increased greatly when certain other drugs are coconsumed, these data indicate that phenylpropanolamine may enhance absorption or inhibit elimination of caffeine and may explain increased side effects reported after their combined use.
Similar articles
-
Clinically significant pharmacokinetic interactions between dietary caffeine and medications.Clin Pharmacokinet. 2000 Aug;39(2):127-53. doi: 10.2165/00003088-200039020-00004. Clin Pharmacokinet. 2000. PMID: 10976659 Review.
-
Dose-dependent response to phenylpropanolamine: inhibition of orthostasis.J Clin Pharmacol. 1991 Jul;31(7):624-35. doi: 10.1002/j.1552-4604.1991.tb03748.x. J Clin Pharmacol. 1991. PMID: 1894758 Clinical Trial.
-
A pharmacodynamic interaction between caffeine and phenylpropanolamine.Clin Pharmacol Ther. 1991 Oct;50(4):363-71. doi: 10.1038/clpt.1991.152. Clin Pharmacol Ther. 1991. PMID: 1914371 Clinical Trial.
-
The effects of phenylpropanolamine on human sympathetic nervous system function.Neuropsychopharmacology. 1988 May;1(2):163-8. doi: 10.1016/0893-133x(88)90008-5. Neuropsychopharmacology. 1988. PMID: 3251497 Clinical Trial.
-
Phenylpropanolamine and other over-the-counter vasoactive compounds.Hypertension. 1988 Mar;11(3 Pt 2):II7-10. doi: 10.1161/01.hyp.11.3_pt_2.ii7. Hypertension. 1988. PMID: 3280497 Review.
Cited by
-
Clinically significant pharmacokinetic interactions between dietary caffeine and medications.Clin Pharmacokinet. 2000 Aug;39(2):127-53. doi: 10.2165/00003088-200039020-00004. Clin Pharmacokinet. 2000. PMID: 10976659 Review.
-
The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations.Psychopharmacology (Berl). 1993;110(3):309-19. doi: 10.1007/BF02251286. Psychopharmacology (Berl). 1993. PMID: 7831424
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical